Zydus starts phase II trial of ZYAN1 for treating anemia in patients with CKD
Zydus announced the initiation of a phase II trial investigating ZYAN1, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anemia associated…
Read More...
Read More...